Patent classifications
A61L2430/00
Methods For Development And Use Of Minimally Polarized Function Cell Micro-Aggregate Units In Tissue Applications Using LGR4, LGR5, And LGR6 Expressing Epithelial Stem Cells
Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.
Cross-linked fatty acid-based biomaterials
Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.
Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal
Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue.
Method of fabricating scaffold for tissue engineering
A method of fabricating a scaffold for tissue engineering that includes a frame structure including one of poly-D-lactic acid and poly-L-lactic acid and a coating layer formed on a surface of the frame structure and including a lactic acid-glycolic acid copolymer. The method includes mixing a first granular porous substance including one of poly-D-lactic acid and poly-L-lactic acid with a second granular porous substance including the lactic acid-glycolic acid copolymer to prepare a mixture, and pressurizing and heating the mixture in a mold. In the heating, the mixture is heated to a temperature greater than or equal to the melting point of the lactic acid-glycolic acid copolymer and less than the melting point of one of poly-D-lactic acid and poly-L-lactic acid.
COMPOSITION BASED ON RECOMBINANT BIOPOLYMERS AND USES OF SAME AS BIO-INK
The present invention refers to compositions comprising recombinant biopolymers made of combinations of monomers of the type “Elastin-like recombinamers” (ELR), monomers comprising the “silk” sequence and/or monomers comprising the HLF sequence that belongs to a natural class of proteins named zippers. Said compositions are useful as bio-ink for 3D printing. Furthermore, the present invention also refers to methods for obtaining the composition of the invention, as well as the 3D biomaterial and to the different uses of the composition and the obtained biomaterial.
Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom
Novel absorbable polymer blends are disclosed. The blends are useful for manufacturing medical devices having engineered degradation and breaking strength retention in vivo. The blends consist of a first absorbable polymeric component and a second absorbable polymeric component. The weight average molecular weight of the first polymeric component is higher than the weight average molecular weight of the second polymeric component. At least at least one of said components is at least partially end-capped by a carboxylic acid group. Further aspects are medical devices made therefrom.
CHITOSAN SUPERFINE FIBER SYSTEMS
The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.
Pancreatic islet-like cell structures and a method of preparing thereof
The invention relates to a method of preparing pancreatic islet-like cell structures characterized by a unique combination of morphological and functional features which make them particularly suitable for use in both clinical and drug screening application, as well as to the pancreatic islet-like cell structures obtained therefrom.
A METHOD FOR BUILDING A STRUCTURE CONTAINING LIVING CELLS
A composition comprising a first material and a second material, wherein said first material is cross-linkable by a first cross-linking reaction and said second material is cross-linkable by a second cross-linking reaction, wherein said first cross-linking reaction and said second cross-linking reaction are inducible by a common activator.
Process for removing growth factors from platelets
In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization. Then at a later date, the freeze-dried product is reconstituted by normal saline for treatment of a patient's wound, for use in a surgical procedure, or for tissue regeneration.